Erratum: The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein(Oncogene(2015)32(3819-3828)10.1038/onc.2012.406);The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein

Oncogene

Volumn 32, Issue 33, 2013, Pages 3819-3828

  Guan, D ^a   Factor, D ^a   Liu, Yu ^a   Wang, Z ^a,b   Kao, H Y ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

capillary tube formation; cell migration; PML; ubiquitination; UHRF1

Indexed keywords

E2D2 PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; REGULATOR PROTEIN; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN PROTEIN LIGASE E3; UHRF1 PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CAPILLARY TUBE; CELL MIGRATION; CELL STRAIN HEK293; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REGULATOR GENE; RING FINGER MOTIF; TUMOR SUPPRESSOR GENE; TURNOVER TIME; UBIQUITINATION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WILD TYPE;

EID: 84882454345     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.314     Document Type: Erratum

References (53)

1. Arita K, Ariyoshi M, Tochio H, Nakamura Y, Shirakawa M. Recognition of hemimethylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature 2008; 455: 818-821.
2. Avvakumov GV, Walker JR, Xue S, Li Y, Duan S, Bronner C et al. Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature 2008; 455: 822-825.
3. Hashimoto H, Horton JR, Zhang X, Bostick M, Jacobsen SE, Cheng X. The SRA domain of UHRF1 flips 5-methylcytosine out of the DNA helix. Nature 2008; 455: 826-829.
4. Bostick M, Kim JK, Esteve PO, Clark A, Pradhan S, Jacobsen SE. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007; 317: 1760-1764.
5. Unoki M, Nishidate T, Nakamura Y. ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene 2004; 23: 7601-7610.
6. Hu L, Li Z, Wang P, Lin Y, Xu Y. Crystal structure of PHD domain of UHRF1 and insights into recognition of unmodified histone H3 arginine residue 2. Cell Res 2011; 21: 1374-1378.
7. Xie S, Jakoncic J, Qian C. UHRF1 double tudor domain and the adjacent PHD finger act together to recognize K9me3-containing histone H3 tail. J Mol Biol 2011; 415: 318-328.
8. Citterio E, Papait R, Nicassio F, Vecchi M, Gomiero P, Mantovani R et al. Np95 is a histone-binding protein endowed with ubiquitin ligase activity. Mol Cell Biol 2004; 24: 2526-2535.
9. Yan F, Tan XY, Geng Y, Ju HX, Gao YF, Zhu MC. Inhibition effect of siRNAdownregulated UHRF1 on breast cancer growth. Cancer Biother Radiopharm 2011; 26: 183-189.
10. Li X, Meng Q, Rosen EM, Fan S. UHRF1 confers radioresistance to human breast cancer cells. Int J Radiat Biol 2011; 87: 263-273.
11. Unoki M, Daigo Y, Koinuma J, Tsuchiya E, Hamamoto R, Nakamura Y. UHRF1 is a novel diagnostic marker of lung cancer. Br J Cancer 2010; 103: 217-222.
12. Daskalos A, Oleksiewicz U, Filia A, Nikolaidis G, Xinarianos G, Gosney JR et al. UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer. Cancer 2010; 117: 1027-1037.
13. Wang F, Yang YZ, Shi CZ, Zhang P, Moyer MP, Zhang HZ et al. UHRF1 promotes cell growth and metastasis through repression of p16(ink4a) in colorectal cancer. Ann Surg Oncol 2012; 19: 2753-2762.
14. Du Z, Song J, Wang Y, Zhao Y, Guda K, Yang S et al. DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. Sci Signal 2010; 3: ra80.
15. Sabatino L, Fucci A, Pancione M, Carafa V, Nebbioso A, Pistore C et al. UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. Oncogene 2012; 31: 5061-5072.
16. Jenkins Y, Markovtsov V, Lang W, Sharma P, Pearsall D, Warner J et al. Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell 2005; 16: 5621-5629.
17. Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L et al. The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression. Oncogene 2012; 31: 4878-4887.
18. Unoki M, Kelly JD, Neal DE, Ponder BA, Nakamura Y, Hamamoto R. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer 2009; 101: 98-105.
19. Yang GL, Zhang LH, Bo JJ, Chen HG, Cao M, Liu DM et al. UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer. Med Oncol 2011; 29: 842-847.
20. Un F, Qi C, Prosser M, Wang N, Zhou B, Bronner C et al. Modulating ICBP90 to suppress human ribonucleotide reductase M2 induction restores sensitivity to hydroxyurea cytotoxicity. Anticancer Res 2006; 26: 2761-2767.
21. Jin W, Chen L, Chen Y, Xu SG, Di GH, Yin WJ et al. UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer. Breast Cancer Res Treat 2010; 123: 359-373.
22. Alhosin M, Sharif T, Mousli M, Etienne-Selloum N, Fuhrmann G, Schni-Kerth VB et al. Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. J Exp Clin Cancer Res 2011; 30: 41.
23. Jeanblanc M, Mousli M, Hopfner R, Bathami K, Martinet N, Abbady AQ et al. The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. Oncogene 2005; 24: 7337-7345.
24. Kim JK, Esteve PO, Jacobsen SE, Pradhan S. UHRF1 binds G9a and participates in p21 transcriptional regulation in mammalian cells. Nucleic Acids Res 2009; 37: 493-505.
25. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990; 347: 558-561.
26. Reineke EL, Kao HY. Targeting promyelocytic leukemia protein: a means to regulating PML nuclear bodies. Int J Biol Sci 2009; 5: 366-376.
27. Reineke EL, Liu Y, Kao HY. Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1. J Biol Chem 2010; 285: 9485-9492.
28. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 2004; 96: 269-279.
29. Fanelli M, Fantozzi A, De Luca P, Caprodossi S, Matsuzawa S, Lazar MA et al. The coiled-coil domain is the structural determinant for mammalian homologues of Drosophila Sina-mediated degradation of promyelocytic leukemia protein and other tripartite motif proteins by the proteasome. J Biol Chem 2004; 279: 5374-5379.
30. Boutell C, Canning M, Orr A. Everett RD. Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitinspecific protease USP7. J Virol 2005; 79: 12342-12354.
31. Louria-Hayon I, Alsheich-Bartok O, Levav-Cohen Y, Silberman I, Berger M, Grossman T et al. E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ 2009; 16: 1156-1166.
32. Yuan WC, Lee YR, Huang SF, Lin YM, Chen TY, Chung HC et al. A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell 2011; 20: 214-228.
33. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008; 10: 538-546.
34. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008; 10: 547-555.
35. Reineke EL, Lam M, Liu Q, Liu Y, Stanya KJ, Chang KS et al. Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. Mol Cell Biol 2008; 28: 997-1006.
36. Jensen K, Shiels C, Freemont PS. PML protein isoforms and the RBCC/TRIM motif. Oncogene 2001; 20: 7223-7233.
37. Felle M, Joppien S, Nemeth A, Diermeier S, Thalhammer V, Dobner T et al. The USP7/Dnmt1 complex stimulates the DNA methylation activity of Dnmt1 and regulates the stability of UHRF1. Nucleic Acids Res 2011; 39: 8355-8365.
38. Ma H, Chen H, Guo X, Wang Z, Sowa ME, Zheng L et al. M phase phosphorylation of the epigenetic regulator UHRF1 regulates its physical association with the deubiquitylase USP7 and stability. Proc Natl Acad Sci USA. 2012; 109: 4828-4833.
39. van Wijk SJ, de Vries SJ, Kemmeren P, Huang A, Boelens R, Bonvin AM et al. A comprehensive framework of E2-RING E3 interactions of the human ubiquitinproteasome system. Mol Syst Biol 2009; 5: 295.
40. Rajakumara E, Wang Z, Ma H, Hu L, Chen H, Lin Y et al. PHD finger recognition of unmodified histone H3R2 links UHRF1 to regulation of euchromatic gene expression. Mol Cell 2011; 43: 275-284.
41. Nady N, Lemak A, Walker JR, Avvakumov GV, Kareta MS, Achour M et al. Recognition of multivalent histone states associated with heterochromatin by UHRF1. J Biol Chem 2011; 286: 24300-24311.
42. Wang DY, Done SJ, McCready DR, Boerner S, Kulkarni S, Leong WL. A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis. Breast Cancer Res 2011; 13: R92.
43. Unoki M, Brunet J, Mousli M. Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis. Biochem Pharmacol 2009; 78: 1279-1288.
44. Terris B, Baldin V, Dubois S, Degott C, Flejou JF, Henin D et al. PML nuclear bodies are general targets for inflammation and cell proliferation. Cancer Res 1995; 55: 1590-1597.
45. Gao C, Cheng X, Lam M, Liu Y, Liu Q, Chang KS et al. Signal-dependent regulation of transcription by histone deacetylase 7 involves recruitment to promyelocytic leukemia protein nuclear bodies. Mol Biol Cell 2008; 19: 3020-3027.
46. Cheng X, Liu Y, Chu H, Kao HY. Promyelocytic leukemia protein (PML) regulates endothelial cell network formation and migration in response to tumor necrosis factor alpha (TNFalpha) and interferon alpha (IFNalpha). J Biol Chem 2012; 287: 23356-23367.
47. Sarkari F, Wang X, Nguyen T, Frappier L. The herpesvirus associated ubiquitin specific protease, USP7, is a negative regulator of PML proteins and PML nuclear bodies. PLoS One 2011; 6: e16598.
48. Canning M, Boutell C, Parkinson J, Everett RD. A RING finger ubiquitin ligase is protected from autocatalyzed ubiquitination and degradation by binding to ubiquitin-specific protease USP7. J Biol Chem 2004; 279: 38160-38168.
49. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 406: 207-210.
50. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol 2002; 4: 1-10.
51. Lim JH, Liu Y, Reineke E, Kao HY. Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover. J Biol Chem 2011; 286: 44403-44411.
52. Khurana S, Chakraborty S, Cheng X, Su YT, Kao HY. The actin-binding protein, actinin alpha 4 (ACTN4), is a nuclear receptor coactivator that promotes proliferation of MCF-7 breast cancer cells. J Biol Chem 2011; 286: 1850-1859.
53. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003; 112: 779-791.